Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Biousian Biosystems Receives US Patent

Published: Tuesday, December 17, 2013
Last Updated: Monday, December 16, 2013
Bookmark and Share
Patent provides composition of matter protection for a series of highly selective delta opioid receptor agonists.

Biousian Biosystems Inc, (BBI) has announced that the U.S. Patent and Trademark Office has issued a patent to BBI (U.S. Patent 8,575,309).

The patent describes a series of highly selective and potent delta opioid receptor agonists for the treatment of acute and chronic pain. One of the molecules covered by the patent is BBI-11008, the company’s lead drug that is positioned as a best-in-class analgesic.

BBI-11008 is an orally available drug that has equivalent efficacy to opioids but exhibits markedly reduced side effects in preclinical models. Due to the unique delta opioid selectivity of BBI-11008, it lacks the toxicities usually associated with mu selective opioid agonists (e.g. morphine), including respiratory distress, GI tract immobility and has no evidence of addiction. The molecule’s performance has been studied in extensive in-vivo preclinical pain studies, funded by multiple NIH SBIR grants.

Ed Bilsky, Founder of Biousian Biosystems and Professor of Biomedical Sciences at the University of New England, said, “Delta opioid receptors were first described in the 1970s, but multiple efforts to develop a highly selective agonist with drug-like properties have failed. Our novel synthetic chemistry applied to naturally occurring enkephalin opioid peptides enable us to impart small-molecule, drug-like properties to peptides. The lead molecule has therapeutic utility across a broad range of pain indications, including neuropathic pain, inflammatory pain, cancer pain and migraine.”

Robin Polt, Founder of Biousian Biosystems and Professor of Chemistry and Biochemistry, and BIO5 at the University of Arizona said, “We are very excited about the prospects for glycopeptide drugs that increase drug stability and increase penetration across the blood-brain barrier and into the central nervous system. Biologically compatible glycosides such as BBI-11008 are metabolized into simple amino acids and sugars that are more properly regarded as nutrients, in contrast to classical opioid alkaloids that produce a cascade of toxic metabolites.”

Mark Philip, acting President of Biousian Biosystems said “We are delighted to have made such rapid progress and achieved proof of principle for both efficacy and safety for BBI-11008 in a range of preclinical models. This, together with the recently-issued patent protection for this series of molecules, encourages us to accelerate the work towards moving the lead candidate into the clinic.”

Biousian is actively exploring both corporate partnerships and/or equity investment to progress this molecule into clinical trials. The company’s business development is being supported by Alacrita Consulting.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
CES Score May Predict Response to Cancer Treatment
Researchers identify new type of biomarker that helps predict prognosis and response to several types of cancer treatment.
Treating Sepsis with Marine Mitochondria
Mitochondrial alternative oxidase from a marine animal combats bacterial sepsis.
New Therapeutic Target for Crohn’s Disease
A promising new target for drugs that treat IBD has been identified along with a possible biomarker for IBD severity.
Researchers Find Fungus-Fighting Compound
A compound has been identifed that blocks growth of a fungus responsible for lung infections and allergic reactions.
Analysing 10,000 Cells Simultaneously
New techniquethat traps 10,000 cells on a single chip has potential for cancer screening for individuals.
Peer Reviewed Study Demonstrates Mass Spec Technique
The peer reviewed study demonstrates MS workflow, TMTCalibrator workflow, which dramatically enhances detection of key early stage Alzheimer’s biomarkers.
Small Molecules Lead to a Big Change in Reaction Outcomes
Scientists have changed the behaviour of a group of molecules involved in carbon-oxygen bond synthesis.
Enhancing Antibiotics to Defeat Resistant Bacteria
Scientists enhance ability of antibiotics to defeat resistant types of bacteria using molecules called PPMOs
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!